Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis

Annals of Neurology

Volumn 59, Issue 2, 2006, Pages 237-247

  Irani, David N ^a,b   Anderson, Caroline ^a   Gundry, Rebekah ^b   Cotter, Robert ^b   Moore, Stacy ^c   Kerr, Douglas A ^a,b   McArthur, Justin C ^a   Sacktor, Ned ^a   Pardo, Carlos A ^a   Jones, Melina ^a   Calabresi, Peter A ^a   Nath, Avindra ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN; CYSTATIN C; CYSTEINE PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; EVOKED RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

ADOLESCENT; ADULT; CATHEPSINS; CYSTATINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; PROTEIN ARRAY ANALYSIS; STATISTICS;

EID: 32044452472     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20786     Document Type: Article

References (21)

1. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004;15:24-30.
2. Dumont D, Noben JP, Raus J, et al. Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004;4:2117-2124.
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
4. Frohman EM, Goodin DS, Calabresi PA, et al. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602-611.
5. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 2002;8:136-142.
6. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-858.
7. Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3:1486-1494.
8. Grzonka Z, Jankowska E, Kasprzykowski F, et al. Structural studies of cysteine proteases and their inhibitors. Acta Biochim Pol 2001;48:1-20.
9. Lofberg H, Grubb AO. Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. Scand J Clin Lab Invest 1979;39:619-626.
10. Abrahamson M, Ritonja A, Brown MA, et al. Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem 1987;262:9688-9694.
11. Balaji KN, Schaschke N, Machleidt W, et al. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med 2002;196:493-503.
12. Greiner A, Lautwein A, Overkleeft HS, et al. Activity and subcellular distribution of cathepsins in primary human monocytes. J Leukoc Biol 2003;73:235-242.
13. Nagai A, Terashima M, Harada T, et al. Cathepsin B and H activities and cystatin C concentrations in cerebrospinal fluid from patients with leptomeningeal metastasis. Clin Chim Acta 2003;329:53-60.
14. Bever CT Jr, Carver DW. Increased cathepsin B activity in multiple sclerosis brain. J Neurol Sci 1995;131:71-73.
15. Sanchez JC, Guillaume E, Lescuyer P, et al. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004;4:2229-2233.
16. Gerhartz B, Abrahamson M. Physico-chemical properties of the N-terminally truncated L68Q cystatin C found in amyloid deposits of brain haemorrhage patients. Biol Chem 2002;383:301-305.
17. Abrahamson M, Mason RW, Hansson H, et al. Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochem J 1991;273:621-626.
18. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
19. Johansson L, Grubb A, Abrahamson M, et al. A peptidyl derivative structurally based on the inhibitory center of cystatin C inhibits bone resorption in vitro. Bone 2000;26:451-459.
20. Barrett AJ, Kembhavi AA, Brown MA, et al. L-trans-epoxysuccinyl- leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 1982;201:189-198.
21. Matsumoto K, Mizoue K, Kitamura K, et al. Structural basis of inhibition of cysteine proteases by E-64 and its derivatives. Biopolymers 1999;51:99-107.